EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer

Stephen Chia iD, Jie Li, Fei Ma, Daniel Stellato, Andriy Danyliv, Ilia Ferrusi, Huilin Hu, Murat Akdere, Andreas Makris

Journal of Comparative Effectiveness Research · 2025-10 · 14 (10)

DOI: 10.57264/cer-2025-0082 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2025-10. Verfasst von Stephen Chia und 8 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer, Vancouver, BC, Canada. Hauptthemen laut MEDLINE: Aminopyridines, Purines, Breast Neoplasms, Benzimidazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based on data from the NATALEE and monarchE trials, respectively. No trials have directly compared efficacy and safety of adjuvant ribociclib and abemaciclib. This study compared relative efficacy and safety of adjuvant ribociclib + NSAI versus abemaciclib + ET using matching-adjusted indirect comparison (MAIC). Materials & methods: Individual patient data from NATALEE and aggregate data from monarchE were analyzed, with patients from NATALEE selected to match the key eligibility criteria of monarchE cohort 1. Unanchored MAIC was used to compare invasive disease-free survival, distant relapse–free survival, and grade ≥3 treatment-emergent adverse events between treatment arms in NATALEE versus monarchE. Cox regression was used to estimate hazard ratios pre- and post-MAIC weighting. Logistic regression was used to estimate odds ratios (ORs).

Results

After weighting, the effective sample size for the ribociclib + NSAI arm of NATALEE was 448. Cox regression yielded similar invasive disease-free survival with weighted ribociclib + NSAI versus abemaciclib + ET (hazard ratio, 0.901; 95% CI: 0.678–1.197). Unweighted efficacy comparisons were consistent with the weighted approach. Lower odds (OR 1) for increased alanine aminotransferase and neutropenia with ribociclib + NSAI versus abemaciclib + ET were noted before and after weighting. Sensitivity analyses were consistent with the primary analysis.

Conclusion

This MAIC suggests similar efficacy between ribociclib + NSAI and abemaciclib + ET but different safety profiles in the HR+/HER2- early breast cancer patient population corresponding to the monarchE cohort 1, which has implications for treatment decisions. This analysis has limitations inherent to unanchored MAIC and should be interpreted in context of the trials and with clinical judgement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesPurinesBreast NeoplasmsBenzimidazolesAromatase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultDisease-Free SurvivalAgedReceptors, ProgesteroneReceptors, Estrogen

Stichwörter der Autor:innen

HER2-negativeabemaciclibearly breast cancerhormone-receptor positivematching-adjusted indirect comparisonribociclib

Substanzen

AminopyridinesPurinesBenzimidazolesAromatase InhibitorsErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneReceptors, EstrogenribociclibabemaciclibERBB2 protein, human

Autor:innen und Institutionen

  • BC Cancer, Vancouver, BC, Canada.
  • Department of Breast & Thyroid Surgery, Guangzhou Women & Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Avalere Health, London, UK.
  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

ORCID-Profile: Stephen Chia

Zitieren

APA

Chia, S., Li, J., Ma, F., Stellato, D., Danyliv, A., Ferrusi, I., Hu, H., Akdere, M., & Makris, A. (2025). Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer. Journal of Comparative Effectiveness Research, 14(10). https://doi.org/10.57264/cer-2025-0082

Vancouver

Chia S, Li J, Ma F, Stellato D, Danyliv A, Ferrusi I, et al. Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer. Journal of Comparative Effectiveness Research. 2025;14(10). doi:10.57264/cer-2025-0082

BibTeX
@article{Chia2025,
  author = {Chia, Stephen and Li, Jie and Ma, Fei and Stellato, Daniel and Danyliv, Andriy and Ferrusi, Ilia and Hu, Huilin and Akdere, Murat and Makris, Andreas},
  title = {Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2025},
  volume = {14},
  number = {10},
  doi = {10.57264/cer-2025-0082}
}
Kostenlos starten →